Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2371-2376

  Ellerhorst, Julie A ^a   Tu, Shi Ming ^a   Amato, Robert J ^a   Finn, Laury ^a   Millikan, Randall E ^a   Pagliaro, Lance C ^a   Jackson, Angela ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESTRAMUSTINE; HYDROCORTISONE; KETOCONAZOLE; VINBLASTINE;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; EDEMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DENSITY; SURVIVAL TIME; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE NEOPLASMS; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; HUMANS; HYDROCORTISONE; KETOCONAZOLE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0031431760     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Catalona, W. J. Management of cancer of the prostate. N. Engl. J. Med., 15: 996-1004, 1994.
2. Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D., and Curley, T. Estramustine and vinblastine: use of prostate-specific antigen as a clinical trial endpoint for hormone-refractory prostatic cancer. J. Urol., 147: 931-934, 1992.
3. Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K., and Comis, R. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol., 10: 1754-1761, 1992.
4. Amato, R. J., Ellerhorst, J., Bui, C., and Logothetis, C. J. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol. Oncol., 1: 168-172, 1995.
5. Sella, A., Kilbourn, R., Amato, R., Bui, C., Zukiwski, A. A., Ellerhorst, J., and Logothetis, C. J. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J. Clin. Oncol., 12: 683-688, 1994.
6. Scher, H. I., and Kelly, W. K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566-1572, 1993.
7. Ewer, M. S., and Benjamin, R. S. Cardiac Complications. In: J. F. Holland, R. C. Bast, Jr., D. L. Morton, E. Frei, III, D. W. Kufe, and R. R. Weichselbaum (eds.), Cancer Medicine, Vol. 2, pp. 3197-3215. Baltimore, MD: Williams & Wilkins Publishers, 1997.
8. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-461, 1958.
9. Pienta, K. J., Redman, B., Hussain, M., Cummings, G., Esper, P. S., Appel, C., and Flaherty, L. E. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol., 12: 2005-2012, 1994.
10. Small, E. J., Srinivas, S., Egan, B., McMillan, A., and Rearden, T. P. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J. Clin. Oncol., 14: 1617-1625, 1996.
11. Small, E. J., Baron, A. D., Fippin, L., and Apodaca, D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol., 157: 1204-1207, 1997.
12. Muscato, J. J., Ahmann, T. A., Johnson, K. M., Wilding, W., Monaghan, G., and Schlossman, D. M. Optimal dosing of ketoconazole (keto) and hydrocortisone (HC) leads to long responses in hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol., 13: 229, 1994.
13. Storlie, J. A., Buckner, J. C., Wiseman, G. A., Burch, P. A., Hartmann, L. C., and Richardson, R. L. Prostate-specific antigen levels and clinical response to low-dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer (Phila.), 76: 96-100, 1995.
14. Kelly, W. K., Curley, T., Leibertz, C., Dnistrian, A., Schwartz, M., and Scher, H. I. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J. Clin. Oncol., 13: 2208-2213, 1995.